Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, ...

Leela Barham looked at what had happened a year after the NHS 10-Year Plan, released in July 2025, included the commitment to ...

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease, after preliminary results proved disappointing. Shares in ...

Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have remained low, with approximately 90-95% of drug candidates failing during ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion ...